LAST UPDATED:
28 November 2022
A visionary scientist like José Baselga comes around once in a generation. A gifted physician-researcher, he experienced triumphs and overcame challenges to help transform cancer treatment for patients around the world. As we approach the one-year anniversary of his passing, we reflect not only on his pioneering achievements and contributions to oncology research and clinical care, but also his lasting impact on individuals, teams and institutions around the world.
José was a fierce opponent of cancer through his determination to understand not just the biology of cancer, but how each patient was experiencing the disease. He had an innate ability to see patterns where others could not, and his tenacity helped to push himself and those around him to ask questions and seek new ways of approaching science. A lifelong student and teacher, he was a mentor who worked to inspire researchers, clinicians and students of all types.
In March 2022, the flagship building on our Gaithersburg, Maryland campus was dedicated as the José Baselga Building at One MedImmune Way, in honour of his visionary leadership. On the same day, the documentary José Baselga: Cancer's Fiercest Opponent had its global premiere inside the building, and the event was attended by José’s family and hundreds of our colleagues.
We continue to honour José’s legacy through several ongoing initiatives, many in collaboration with partner institutions and organisations to maximise impact to the cancer research and rare disease communities. These initiatives include:
- Launch of José Baselga Innovative Disruption Program in Barcelona, in collaboration with Vall d’Hebron Institute of Oncology, to strengthen preclinical and translational research
- Support for clinician-scientists in oncology translational research through fellowships and awards in coordination with AACR, ESMO and ASCO professional societies
- Rededication of a programme championed by José, now called AZ Baselga Cancer Research Scholars Program. This competitive, two-year immersive education and research programme provides valuable opportunities for early-career oncologists to gain first-hand experience in drug development with the aim of transforming patient care.
